Tasermity (sevelamer hydrochloride)
- Region
- 🇪🇺 EU
- Active substance
- sevelamer hydrochloride
- Company
- Genzyme Europe BV
- Status
- Lapsed
- Therapeutic area
- Hyperphosphatemia; Renal Dialysis
- EU approval
- Wed 25 Feb 2015
- Application
- EMEA/H/C/003968
- ATC
- V03AE02
- Official record
- www.ema.europa.eu
Indication
Tasermity is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Regulatory milestones
No milestones recorded in the last year.
Follow Tasermity
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.